Defensive Assets Gain Traction in Hong Kong as Lithium and Biotech Firms Advance RestructuringGlobal Report·1 day ago, 04:15 AM02687+4.25%02171+4.36%
‘Systemic leap’: China’s drug innovation push yields bumper cropSCMP·Jul 20 at 06:03 PM02171+4.36%688192-0.22%
Hong Kong's Cross-Sector Signals: From AI Infrastructure to Global BiopharmaGlobal Report·Jul 18 at 04:12 AM01686+6.15%02858+0.75%
CARsgen files HKEX next-day disclosure return, issues 2,000 new shares via option exercisePUBT·Jul 17 at 09:36 AM02171+4.36%
CARsgen says satri-cel gastric cancer consolidation trial shows no recurrences to datePUBT·Jul 14 at 07:00 PM02171+4.36%
National Electronics files HKEX next-day disclosure return on share repurchase for cancellation at HKD 0.36PUBT·Jul 7 at 06:25 AM002130.00%
CARsgen Launches Discretionary Share Buyback Worth Up to 5% of CapitalTip Ranks·Jun 25 at 11:38 PM02171+4.36%
Sangamo holds a bankruptcy sale; VCs back a China-linked Beam competitorbiopharmadive·Jun 24 at 09:32 AMMKKGY+0.73%SNY-4.37%
China’s CARsgen Slides for Second Day on Hefty Price Tag for World’s First Solid Tumor CAR-T TherapyYicai·Jun 24 at 07:03 AM02171+4.36%
Keji Bio Plunges 8% On Real Return From CAR-T HighsHK Stock Market Update·Jun 23 at 01:14 AM02171+4.36%
Juno Bio-B gains after CAR-T product wins global-first solid tumor approvalHK Stock Market Update·Jun 22 at 08:58 PM02171+4.36%
CARsgen Wins First-Ever Global Approval for Solid-Tumor CAR T Therapy in ChinaTip Ranks·Jun 22 at 03:42 AM02171+4.36%
